Celanese and secarna pharmaceuticals enter into rna research collaboration for long-acting antisense therapies

Dallas, tx and martinsried, germany / accesswire / march 20, 2024 / celanese corporation (nyse:ce), a global specialty materials and chemical company, and secarna pharmaceuticals gmbh & co. kg, a leading independent european antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (asos). asos are synthetic molecules designed to target specific messenger rna to prevent the production of proteins implicated in the progression of a wide range of diseases including cardiometabolic, central nervous system, oncological and rare diseases.
CE Ratings Summary
CE Quant Ranking